Molecular Targeting Technologies, Inc. and Molecular Theranostics Center of Singapore Receive HSA Approval for Clinical Trial Authorization for EBTATE® in Nasopharyngeal Cancer

[ad_1] Molecular Targeting Technologies, Inc. and Molecular Theranostics …  WV News [ad_2] Source link

Everest Medicines Announces New Drug Application Acceptance by Singapore HSA for Nefecon for the Treatment of Primary IgA Nephropathy

[ad_1] Nefecon NDA is currently under Priority Review in China and expected to receive approval in 2H 2023 SHANGHAI, April 5, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or…